University of Campinas | Brazil
Dr. Giorgio Antoniolli is a researcher specializing in organic and medicinal chemistry, with extensive experience in the design, synthesis, and evaluation of bioactive organic compounds. His work primarily focuses on nitrogen-containing heterocyclic scaffolds, such as quinazolinones and hydrazides, targeting potential anticancer and neuroprotective applications. He has developed and optimized synthetic routes for these compounds, employing advanced characterization techniques including ¹H and ¹³C NMR, Infrared (IR) Spectroscopy, and Mass Spectrometry (MS).
His research integrates both experimental and computational approaches, utilizing in silico pharmacological tools such as SwissADME and ProToxIII to predict absorption, distribution, metabolism, excretion, and toxicity (ADMET) properties. These predictions are complemented by in vitro enzymatic inhibition assays to evaluate biological activity, particularly focusing on targets relevant to cancer and neurodegenerative diseases. Additionally, his work on chalcones and related derivatives has contributed to understanding their inhibitory effects on enzymes like acetylcholinesterase and β-secretase (BACE-1).
Beyond laboratory research, he has been actively involved in mentoring and supervising undergraduate researchers, fostering the development of the next generation of scientists. His integrated approach combines organic synthesis, computational pharmacology, and biochemical evaluation, contributing to the discovery and development of novel therapeutic agents with enhanced efficacy and safety profiles.
Featured Publications:
El Safadi, M., Alkhoshaiban, A. S., Ashfaq, H., Antoniolli, G., Al-Emam, A., & Hassan, H. M. (2026). Cirsiliol confers cardio-protection against sunitinib induced cardiotoxicity via synergistic modulation of SIRT1/FOXO3a and endothelin axis: A biochemical, histopathological, and computational experimentation. Tissue and Cell, 98, 103129.
Antoniolli, G., de Moraes, G. R., Neves da Costa, R. P., Rosendo de Campos, G. A., & Coelho, F. (2025). Advances in xanthine oxidase inhibition: A review of potential bioactive synthetic compounds. Archiv der Pharmazie, 358(8), e70079.
Antoniolli, G., Lima, K., Franchi, G. C., Passos Lima, C. S., Machado-Neto, J. A., & Coelho, F. (2025). Synthesis and evaluation of 2-substituted quinazolin-4(3H)-ones as potential antileukemic agents. ACS Omega, 10(31), 34882–34894.
Antoniolli, G., Passos Lima, C. S., & Coelho, F. (2025). Recent advances in the investigation of the quinazoline nucleus and derivatives with potential anticancer activities. Future Medicinal Chemistry, 17(10), 1193–1211.
Hassan, H. M., Bibi, A., Antoniolli, G., El Safadi, M., Alzahrani, K. J., Alzahrani, F. M., & Aljohani, A. (2025). Melanoxetin modulates oxidative, inflammatory and apoptotic pathways to confer cardio-protection against flumethrin-induced sub-chronic toxicity. Toxicon, 267, 108580.
Badamasi, H., Naeem, Z., Antoniolli, G., Kumar, A. P., Olaleye, A. A., Sadiq, I. S., & Durimin-iya, N. I. (2025). A review of recent advances in green and sustainable technologies for removing 4-nitrophenol from the water and wastewater. Sustainable Chemistry and Pharmacy, 43, 101867.
Hassan, H. M., El Safadi, M., Mustfa, W., Tehreem, S., Antoniolli, G., Mehreen, A., & Ali, A. (2024). Pharmacotherapeutic potential of pratensein to avert metribuzin instigated hepatotoxicity via regulating TGF-β1, PI3K/Akt, Nrf-2/Keap-1 and NF-κB pathway. Tissue and Cell, 91, 102635.
El Safadi, M., Ahmad, Q.-u.-A., Majeebullah, M., Ali, A., Al-Emam, A., Antoniolli, G., Shah, T. A., & Salamatullah, A. M. (2024). Palliative potential of velutin against abamectin induced cardiac toxicity via regulating JAK1/STAT3, NF-κB, Nrf-2/Keap-1 signaling pathways: An insight from molecular docking. Pesticide Biochemistry and Physiology, 205, 106117.